Showing papers by "Chungyeul Kim published in 2018"

Recurrence prediction using microRNA expression in hormone receptor positive breast cancer during tamoxifen treatment

Abstract: Purpose: To identify miRNAs associated with distant recurrence during tamoxifen treatment and build a recurrence prediction model.Materials and methods: We measured the expression of five m...

Recurrent solitary fibrous tumor of the breast: Magnetic resonance imaging and pathologic findings.

Abstract: A 63‐year‐old woman visited our institution for right mastalgia lasting for two months. On admission, mammography and ultrasonography (US) were performed and revealed relatively well‐ circumscribed, ovoid shaped mass. This patient received excisional mass biopsy and wide excision, and the pathologic diagnosis was confirmed as solitary fibrous tumor (SFT) of the breast. After 6 months, she referred to our hospital again for rapidly growing mass for 1 month. The patient underwent US with a 4‐15 MHz linear array transducer (Aix en Provence, Super‐Sonic imagine, France). Her breast US revealed a heterogeneous echoic, bilobulated mass with microlobulated margin at the lower portion of previously post‐operation site (Figure 1A, B). On dynamic contrast‐enhanced magnetic resonance imaging (MRI) of both breasts (3.0T Skyra, Simens, Erlangen, Germany), a bilobulated oval shape with well‐ circumscribed margin was low signal intensity on T1WI (Figure 2A) and heterogeneously high signal intensity on T2WI (Figure 2B). This mass demonstrated a homogeneously enhancing pattern with internal necrotic portion (Figure 2C) with a type III kinetic curve; rapid enhancement and washout pattern analyzing computer‐aided diagnosis (Figure 2D). Once again, we surgically confirmed judging pathologically identical to the previous tumors; SFT Microscopic examination (Figure 3) demonstrated a proliferation of bland‐looking ovoid to short spindle cells, closely packed and haphazardly arranged within a fibrous stroma (Figure 3A, H&E×200). Immunohistochemically, neoplastic cells showed diffuse staining with CD34 (Figure 3B, ×100) while the cells were completely negative for c‐kit, SMA, S‐100, CD10, and desmin. Solitary fibrous tumor (SFT) is an uncommon group of spindle cell neoplasm, categorized under intermediate fibroblastic tumor having rarely metastasis. In addition, SFT is very rare in the breast, with <20 cases reported in the English literature without any case involving local recurrence or metastases. Our case is very unusual in that SFT of the breast was recurrent and is the first report showing MRI findings. MRI of SFT is relatively nonspecific, representing a well‐ defined lobulated lesion with geographic enhancement. Most

Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit.

Abstract: Currently the 21-gene recurrence score (RS) assay called Oncotype DX is recommended by the National Comprehensive Cancer Network guideline for defining the benefit of chemotherapy. To overcome the cost disadvantages of the Oncotype DX assay and the turnaround time, a multigene assay was examined to compare the correlation of the RS and the predicted score (PS) of the present study. Paraffin-embedded tissues of 50 cases with early-stage estrogen receptor (ER)-positive breast cancer, who underwent the Oncotype DX test were used. A total of 149 candidate genes with high correlation to the RS were identified, in another project (Lee et al, unpublished data). Reverse transcription-quantitative polymerase chain reaction biomark assays were conducted using the dynamic array integrated fluidic circuit and the correlation analysis was performed with BRB ArrayTools. A predictive model was developed by the coefficient and gene expression, and 41 genes were identified. If the cut-off was ≥18, the predicted model was 18/50 cases, and the RS was 19, indicating that the differential rate of predicted response against RS was 2%. If the cutoff was ≥11, the predicted model was 38/50 cases and the RS was 34, indicating a difference of 8%. Genes common to the Oncotype DX and the Biomark assay include marker of proliferation Ki-67, aurora kinase A, Erb-B2 receptor tyrosine kinase 2, glutathione S-transferase Mu 1, estrogen receptor 1, progesterone receptor, B-cell lymphoma 2, signal peptide CUB domain EGF-like 2 and 5 reference genes. The remaining 28 genes are involved in various pathways and functions. This result indicates that there is a significant correlation between PS and RS scores, although validation of results is required to accurately determine the risk of distant recurrence. The Biomark assay is an easy and inexpensive way to measure mRNA expression. The present study demonstrates the possibility of the Biomark assay as an alternative for defining chemotherapy benefit in individual patients with ER-positive early-stage breast cancer.